Since 2017, the Vermont Tobacco Control Program (VTCP) has worked to reduce the impact of flavored tobacco products on Vermonters. With the proposed U.S. Food and Drug Administration (FDA) rules banning menthol cigarettes and flavored cigars and proposed legislation banning sales of all menthol and flavored tobacco products in Vermont, VTCP prioritized resources to support cessation among Vermonters who use menthol tobacco products. In March 2021, VTCP began offering a tailored quitline protocol for adults who use menthol tobacco, including financial incentives, for completed coaching sessions. From March 2021 to May 2022, 66 quitline callers enrolled in the menthol incentive protocol, representing 8% of all quitline callers and 25% of participants in the state's quitline incentive programs. A greater proportion of callers in the menthol incentive program completed three or more quitline calls (58% vs. 38%) and enrolled in phone and text support (61% vs. 32%). Quitline callers enrolled in any incentive protocols (menthol, Medicaid/uninsured, or pregnant) were more likely to request one or two forms of nicotine replacement therapy (NRT). Quitlines remain an effective, evidence-based method of tobacco cessation, especially in reaching vulnerable populations. Given the targeted marketing of menthol brands to Black and African American populations, LGBTQ+ populations, youth, and neighborhoods with lower incomes, addressing menthol cigarette use is key to improving health equity and health of Vermonters. Early data indicates that the use of financial incentives can increase engagement with a state quitline among menthol tobacco users through greater completion of cessation coaching calls, enrollment in text message support, and NRT usage.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611895 | PMC |
http://dx.doi.org/10.1177/15248399231171143 | DOI Listing |
Biomarkers
January 2025
Juul Labs, Inc., Washington DC.
Introduction: Adults who switch from smoking cigarettes to use of electronic nicotine delivery systems (ENDS) may reduce their exposure to harmful and potentially harmful constituents (HPHCs). This study assessed changes in exposure to HPHCs, assessed via biomarkers of exposure (BOEs), among adults who switched to a new ENDS product.
Methods: Adults who smoke cigarettes (N = 89) were randomized to: (1) switch completely to using JUUL2 Virginia Tobacco (N = 24) or Polar Menthol (N = 24); (2) continue smoking usual brand (UB) cigarettes (N = 21); or (3) abstain from all tobacco/nicotine products (N = 20) for six days.
Addiction
December 2024
Center for Tobacco Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Addiction
December 2024
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Aims: To determine patterns of e-cigarette flavour use (sweet, tobacco, menthol/mint) in interventional studies of e-cigarettes for stopping smoking, and to estimate associations between flavours and smoking/vaping outcomes.
Methods: Update of secondary data analyses, including meta-analyses subgrouped by flavour provision and narrative syntheses, incorporating data from January 2004 to February 2024. Eligible studies were identified from a Cochrane review.
Chem Res Toxicol
December 2024
Office of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, Maryland 20993, United States.
Nicotine salt e-liquids are widely used in pod-style and disposable electronic nicotine delivery systems (ENDS). Studying the physical and chemical properties of their emissions can inform their toxicological impact. A prior companion study reported the harmful and potentially harmful constituents (HPHCs) and aerosol particle sizes produced from laboratory-made nicotine salt and freebase nicotine e-liquids to assess the effects of varying nicotine salts and nicotine protonation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!